http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Practice guidelines for managing extrahepatic biliary tract cancers
Hyung Sun Kim,Mee Joo Kang,Jingu Kang,Kyubo Kim,Bohyun Kim,Seong-Hun Kim,Soo Jin Kim,Yong-Il Kim,Joo Young Kim,Jin Sil Kim,Haeryoung Kim,Hyo Jung Kim,Ji Hae Nahm,Won Suk Park,Eunkyu Park,Joo Kyung Par The Korean Association of Hepato-Biliary-Pancreati 2024 Annals of hepato-biliary-pancreatic surgery Vol.28 No.2
Backgrounds/Aims: Reported incidence of extrahepatic bile duct cancer is higher in Asians than in Western populations. Korea, in particular, is one of the countries with the highest incidence rates of extrahepatic bile duct cancer in the world. Although research and innovative therapeutic modalities for extrahepatic bile duct cancer are emerging, clinical guidelines are currently unavailable in Korea. The Korean Society of Hepato-Biliary-Pancreatic Surgery in collaboration with related societies (Korean Pancreatic and Biliary Surgery Society, Korean Society of Abdominal Radiology, Korean Society of Medical Oncology, Korean Society of Radiation Oncology, Korean Society of Pathologists, and Korean Society of Nuclear Medicine) decided to establish clinical guideline for extrahepatic bile duct cancer in June 2021. Methods: Contents of the guidelines were developed through subgroup meetings for each key question and a preliminary draft was finalized through a Clinical Guidelines Committee workshop. Results: In November 2021, the finalized draft was presented for public scrutiny during a formal hearing. Conclusions: The extrahepatic guideline committee believed that this guideline could be helpful in the treatment of patients.
Kim, Mi-Kyung,Kim, Min A,Kim, Haeryoung,Kim, Yong-Beom,Song, Yong-Sang Hindawi Publishing Corporation 2014 BioMed research international Vol.2014 No.-
<P>Epithelial-mesenchymal transition (EMT) has been suggested to contribute to tumor progression and acquisition of therapeutic resistance. To assess the clinical significance of EMT-associated proteins, we evaluated the expression of Snail and Slug, the key regulators of EMT, in the primary ovarian cancer samples (<I>n</I> = 103) by immunohistochemistry. Snail was differentially expressed according to the histologic subtype (<I>P</I> = 0.001) and was predominantly expressed in serous and endometrioid types. In the serous and endometrioid adenocarcinomas, the expression of Snail remained high across the stage and grade, suggesting its role in the early phase of carcinogenesis. However, the expression of Snail and Slug was not related to chemoresistance and poor prognosis and did not serve as independent predictive or prognostic marker.</P>
( Haeryoung Kim ),( Young-joo Kim ),( Hyungjin Rhee ),( Jeong Eun Yoo ),( Venancio A. F. Alves ),( Gi Jeong Kim ),( Hye Min Kim ),( Paulo Herman ),( Aline Chagas ),( Young Nyun Park ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: The scirrhous variant of hepatocellular carcinoma (S-HCC) and fibrolamellar HCC (FL-HCC) are less common subtypes of HCC that are characterised by abundant fibrous stroma. Here, we aimed to investigate differences in the tumour microenvironment and the tumour epithelial cell characteristics of S-HCC and FL-HCC. Methods: Whole tissue sections of 17 S-HCCs and 9 FL-HCCs were subjected to immunohistochemical stains for K7, K19, EpCAM, CD56/NCAM, CD163, CD68, pSTAT3, FAP, CCN2 and Ki-67. Results: FL-HCC patients were younger than S-HCC patients (p<0.001), and chronic liver disease was seen in the background of 88.2% of S-HCC and in none of the FL-HCC. CD68 and CD163-positive tumour-infiltrating macrophages and FAP-positive cancer-associated fibroblasts (CAFs) were more abundant in the stroma of S-HCCs compared to FL-HCCs (p<0.05, all). Tumour epithelial K19 expression was more frequent in S-HCCs compared to FL-HCCs (p=0.023). Significant positive correlations were seen between pSTAT3 expression status in tumour epithelial cells and CAFs, the extent of stromal CAF and macrophage infiltration and K19 expression status. No significant differences were seen for K7, EpCAM, CD56/NCAM, CCN2 expression and Ki-67 labelling index between S-HCCs and FL-HCCs. Conclusions: S-HCC and FL-HCC are subtypes of HCC with extensive fibrosis, and the nature of the fibrous stroma differs between them. While the stroma of FL-HCC is composed of dense lamellated collage nous bands with sparse cellular components, S-HCC demonstrates more abundant CAF and tumour-infiltrating macrophages, and stemness- related marker expression, suggesting the presence of a complex tumour microenvironment that may influence the aggressive behaviour of these tumours.
Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer.
Suh, Dong Hoon,Kim, Min A,Kim, Haeryoung,Kim, Mi-Kyung,Kim, Hee Seung,Chung, Hyun Hoon,Kim, Yong-Beom,Song, Yong Sang Springer-Verlag Italia 2014 Clinical and experimental medicine Vol.14 No.3
<P>This aim of this study was to evaluate the relationship between hexokinase II expression and chemoresistance in epithelial ovarian cancer. One hundred and eleven paraffin-embedded specimens from patients with epithelial ovarian cancer were immunohistochemically stained for hexokinase II. Subsequently, the association between hexokinase II overexpression and clinicopathologic characteristics including chemoresistance was assessed. Survival analyses were also performed for evaluating the prognostic value of hexokinase II overexpression. Tumor recurrence within 6 months after termination of first-line chemotherapy was considered to indicate chemoresistance. Hexokinase II overexpression was associated with chemoresistance (p = 0.029) and was an independent risk factor for chemoresistance [odds ratio (OR) 3.37; 95 % confidence interval (CI) 1.07-10.62; p = 0.038] along with non-optimal debulking surgery (OR 4.93; 95 % CI 1.43-16.98; p = 0.011). Hexokinase II overexpression was significantly associated with decreased progression-free survival (p = 0.002) and showed a similar trend for overall survival (p = 0.101). Cox regression analysis revealed that hexokinase II overexpression was an independent prognostic factor for early recurrence (hazard ratio 2.63; 95 % CI 1.40-4.92; p = 0.002). Our findings suggest that hexokinase II overexpression is associated with short progression-free survival, which could be associated with chemoresistance in epithelial ovarian cancer.</P>
( Dong Hoon Suh ),( Min A Kim ),( Haeryoung Kim ),( Mi Kyung Kim ),( Hee Seung Kim ),( Hyun Hoon Chung ),( Yong Beom Kim ),( Yong Sang Song ) 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.98 No.-
Overexpression of hexokinase (HK) II in many cancer cells is thought to provide cancer cells with an anti-apoptotic feature. This study aimed to evaluate the prognostic values of the HK II overexpression in relation to the chemoresistance in epithelial ovarian cancer (EOC). One hundred eleven paraffin embedded specimens from patients with EOC were immunohistochemically stained for HK II protein. Staining patterns were analyzed according to clinicopathologic characteristics including chemoresistance, defined as tumor recurrence <6 months after last chemotherapy. Overexpression of HK II was detected in 48.2% of all patients. Cytoplasmic and nuclear expressions of HK II were observed in 83 (75.5%) and 34 (30.9%), respectively. At a median follow-up of 39 months (range 0-94 months), tumor recurred in 55 (49.5%) and 29 (26.1%) were chemoresistant. HK II overexpression was significantly associated with chemoresistance and recurrence (p=0.029 and p=0.022, respectively), however, advanced stage with a marginal significance (p=0.055). Advanced stage (odds ratio [OR] 6.83; 95% confidence interval [CI] 1.14-41.07; p=0.036) and non-optimal debulking (OR 4.61; 95% CI 1.30-16.30; p=0.018), but not HK II overexpression (OR 2.79, 95% CI 0.88-8.81; p=0.082), were the independent risk factors for chemoresistance. Nevertheless, progression-free survival (PFS) was shorter for patients with HK II overexpression than those without overexpression (p=0.030). Cox proportional hazard regression analysis revealed that HK II overexpression was the independent prognostic factor for recurrence (hazard ratio [HR] 3.30; 95% CI 1.78-6.10; p=0.014). Nuclear expression of HK II was observed significantly more in advanced stage tumor than early stage tumor (p=0.044). Our findings suggest that overexpression of HK II might be a useful prognostic marker for predicting recurrence, but not chemoresistance, in patients with EOC.
Shin Myung Kang,Moo Suk Park,Joon Chang,Haeryoung Kim,Dong-Hwan Shin,Se Kyu Kim,Kyung Young Chung,Dae Joon Kim,Joo Hyuk Sohn,최성호,Jeongmi Kim,Eun Jin Yoon,Joo-Hang Kim 대한암학회 2005 Cancer Research and Treatment Vol.37 No.4
Purpose: A chemosensitivity test can reflect the differences in responses of individual cancer patients to chemotherapeutic agents. The adenosine triphosphatebasedchemotherapy response assay (ATP-CRA)is an accurate method, which does not require a large amount of tissue specimen. So far, no studies have evaluated the utility of the ATP-CRA in Korea. Therefore, we investigated the clinical usefulness of the ATP-CRA in 53 patients with lung cancer.Materials and Methods: Tumor tissues were obtained from bronchoscopic biopsies or surgical resections. The validity of ATP-CRA was assessed focusing on the success rate, experimental error level (intraassay mean coefficient of variation [CV]) and reproducibility.Results: The overall success rate of ATP-CRA was 90.6% (48/53). Normal cells were effectively eliminated from the tumor tissues with the use of ficoll gradient centrifugation and immunomagnetic separation, which was confirmed using loss of heterozygosity analysis of the 3p deletion. The mean CV of ATP assays was 10.5± 4.6%. The reproducibility of ATP assays was 94±3.8%. The results of the ATP assays were reported to physicians within 7 days of specimen collection. More than 6 anticancer drugs were tested on the tumor specimens obtained from bronchoscopic biopsies.Conclusion: The ATP-CRA is a stable, accurate and potentially practical chemosensitivity test in patients with lung cancer.